Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT05163600
Recruiting Not applicable

The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR)

NCT05163600 · tracked via the Priya Life Science Switzerland tracker
Phase
Not applicable
Started
2022-05-20
Last updated
2026-07-07

Condition(s) studied

COPD

Investigational drug(s) / intervention(s)

BFR-CYC 50% peak / 50% AOP (exhaustive)BFR-CYC 3x2minBFR Resistance 80% LOPBFR REsistance 48% vs. 80% LOP

BFR-CYC 50% peak / 50% AOP (exhaustive): BFR-CYC: Continuous cycling at 50% peak work rate (PWR) with bilateral thigh cuffs inflated to 50% limb occlusion pressure (LOP). A maximum duration of 30 minutes is applied as a safety limit.

BFR-CYC 3x2min: BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals.

BFR Resistance 80% LOP: BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions).

BFR REsistance 48% vs. 80% LOP: * BFR at 40% LOP * BFR at 80% LOP All sessions will be conducted on a leg press device under standardized laboratory conditions. Pneumatic cuffs will be applied to the proximal thigh of the right leg. Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.

Study summary

The investigators hypothesize that BFR exercise regimens result in a different acute cardiorespiratory response pattern compared to traditional exercise regimens. Furthermore, the investigators hypothesize that these patterns differ between healthy participants and participants with COPD.

Regarding secondary objective, the investigators hypothesize that BFR results in lower blood pressure responses compared to traditional exercise training in both healthy and COPD participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion and exclusion for the healthy participants are defined by the following criteria. Inclusion criteria: * Age ≥ 18 years * Clinically healthy Exclusion criteria: * Physical or intellectual impairment precluding informed consent or protocol adherence * Non-German speaking (precluding informed consent) * Pain during exercise of any origin * Pregnancy * History of thromboembolic event in the lower extremity * Resting systolic blood pressure \<100 mmHg Inclusion and exclusion for the COPD participants are defined by the following criteria. Inclusion criteria: * Age ≥ 18 years * Diagnosed COPD according to GOLD-guidelines12 Exclusion criteria: * Physical or intellectual impairment precluding informed consent or protocol adherence * Non-German speaking (precluding informed consent) * Acute or recent (within the last 6 weeks) exacerbation of COPD * Pain during exercise of any origin * Pregnancy * History of thromboembolic event in the lower extremity * Resting systolic blood pressure \<100 mmHg

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Zürich Zurich Canton of Zurich Recruiting

More University of Zurich trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05163600 on ClinicalTrials.gov ↗ ← All trials in Switzerland